Diabetes
Refine Search
Biotechnology
Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration and license agreement with privately-held UK firm Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema (DME). 6 September 2013
Pharmaceutical
Danish insulin giant Novo Nordisk (NOV: N) saw its shares fall 2.8% to 936 Danish kroner yesterday (September 3), after the company confirmed that it had lost out on two diabetes therapy contracts in the USA. 4 September 2013
Biotechnology
The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both positive and negative clinical trials results (see also recent stories by The Pharma Letter). 3 September 2013
Pharmaceutical
Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with MSD KK, the local unit of US pharma giant Merck & Co (NYSE: MRK), for ipragliflozin L-proline (development code: ASP1941), a SGLT2 inhibitor. 2 September 2013
Pharmaceutical
Denmark's Zealand Pharma (Nasdaq OMX: ZEAL) has announced an exclusive peptide drug R&D collaboration agreement with US pharma major Eli Lilly (NYSE: LLY) to design and develop potentially novel therapeutic peptides for type 2 diabetes and obesity. 29 August 2013
Pharmaceutical
The expected rise in diabetes is encouraging pharma companies to race to launch type 2 diabetes drugs, according to market analysts Frost & Sullivan. 29 August 2013
Biotechnology
Canada's Sirona Biotech (TSX VENTURE:SBM) has signed a letter of intent to provide an exclusive license to Wanbang Pharma to develop and commercialize Sirona's SGLT2 inhibitor in the People's Republic of China (PRC). 22 August 2013
Pharmaceutical
The increased prescribing of antipsychotics for children and youth has heightened concerns that this practice increases the risk of type 2 diabetes mellitus, according to a new study published in the journal JAMA Psychiatry on August 21. 22 August 2013
Pharmaceutical
Danish insulin giant Novo Nordisk (NOV: N) said late yesterday (August 21) that Jesper Hoiland has been appointed as president of Novo Nordisk Inc, the company's North American affiliate. The appointment became effective August 1, 2013. 21 August 2013
Pharmaceutical
Elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by German family-owned Boehringer Ingelheim and US drug major Eli Lilly (NYSE: LLY) as Trajenta and Tradjenta, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo. 15 August 2013
Pharmaceutical
There was good news for loss-making US drugmaker MannKind (Nasdaq: MNKD), when the company announced positive preliminary results from Study 171, a Phase III clinical trial of Afrezza (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's next-generation (Gen2) inhaler (also known as the Dreamboat inhaler), in patients with type 1 diabetes. 15 August 2013
Pharmaceutical
As part of a new collaboration, the USA's Sanford-Burnham Medical Research Institute at Lake Nona revealed it is working with USA-based Pfizer NYSE: PFE), still the world's largest drugmaker by sales, to identify new therapeutic targets for preventing and treating complications of obesity and diabetes. 14 August 2013
Pharmaceutical
US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into an exclusive agreement with US drug major Merck & Co (NYSE: MRK) to co-promote Merck's type 2 diabetes therapies Januvia (sitagliptin) and the sitagliptin family of products in the long-term care institutional setting in the USA, beginning in October. 13 August 2013
Pharmaceutical
Teplizumab, an experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the Phase III clinical trial, reports EurekAlert. 11 August 2013
Pharmaceutical
The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow 10% annually, reaching $3.5 billion in 2017, according to a new report from health care advisory firm Decision Resources. 9 August 2013
Pharmaceutical
Danish insulin giant Novo Nordisk (NOV: N) posted second quarter 2013, showing that earnings before interest and tax (EBIT) rose 12.3% to 8.59 billion Danish kroner, beating the average 8.27 billion kroner forecast in a Reuters poll of analysts, sending the firm's shares 2.2% higher to 983 kroner in early trading this morning (August 8). 8 August 2013
Pharmaceutical
Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck & Co (NYSE: MRK) within the scope of Merck's product manufacturing localization strategy in Russia. 8 August 2013
Pharmaceutical
UK pharma giant GlaxoSmithKline (LSE: GSK) revealed on Friday (August 2) that the US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes, has been extended by three months to April 15, 2014 to provide time for a full review of information submitted by GSK in response to the Food and Drug Administration's requests. 3 August 2013
Biotechnology
Russian biotechnology company Bioran plans to invest up to 14 billion roubles ($427 million) in the establishment of a plant for the production of insulin, according to local reports. 2 August 2013
Pharmaceutical
German family-owned drug major Boehringer Ingelheim presented its major pipeline developments at an R&D discovery day on Wednesday. 2 August 2013
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze